# November 10, 2026 — Scheduled focused research update

[Home](../README.md) · [Latest](../LATEST.md) · [Website](https://medicineahead.com)

**Scheduled trigger:** November 10, 2026, 9 a.m. America/New_York. **Completion:** 2026-11-11T13:10:21.246438+00:00. Source discovery was bounded through November 10; retrieval/appraisal continued November 11. This is a focused, incomplete review across all 32 active condition topics, not a completed worldwide census. All 33 comprehensive successful-check timestamps and baseline flags are preserved.

**Recorded:** 58 distinct new records, of which 47 are selected feed findings; recovered historical baselines and administrative-only changes remain separately labeled. Duplicate prior events are not re-alerted.

## Findings

- **2026-11-10 — Pelacarsen’s atherosclerosis program has stopped; the extension registry now records termination.** Recovered sponsor decision and newly posted registry status. Novartis ended the pelacarsen ASCVD program in an October 16 patient letter; the November 10 registry now records its safety extension as terminated. This is separate from the November 7 numerical efficacy report. [Full notes](../topics/07_cardiovascular.md#note-2026-11-10-pelacarsen-ascvd-development-discontinued).
- **2026-11-10 — HEART-3 now records recruitment and an actual September start.** Newly posted registry recruitment milestone; no outcomes. VERVE-102’s randomized Phase 2 HEART-3 trial now lists recruiting and an actual September 24 start. LDL lowering and long-term safety remain to be established in this trial. [Full notes](../topics/07_cardiovascular.md#note-2026-11-10-verve102-heart3-recruiting).
- **2026-11-07 — ZEUS’s full conference account adds event counts and harms to the known neutral topline.** Official conference numerical report; July negative result already saved. ZEUS’s fuller report confirms that lower inflammatory markers did not establish fewer cardiovascular events in adults with ASCVD and CKD; the July HR was already public. [Full notes](../topics/07_cardiovascular.md#note-2026-11-10-zeus-full-aha-report).
- **2026-11-09 — Retatrutide’s kidney trial reports a null measured-GFR primary comparison.** Original randomized Phase 2b registry result tables. In a 146-person CKD trial, retatrutide did not improve the 24-week measured-GFR primary comparison. A smaller albuminuria analysis favored treatment; neither establishes prevention of kidney failure. [Full notes](../topics/17_kidney.md#note-2026-11-10-retatrutide-transcend-ckd-registry-results).
- **2026-11-09 — MZE829 completes enrollment in its separate HORIZON kidney study.** Sponsor-reported enrollment milestone and forecasts. Maze reports over 50 enrolled in the Phase 2 MZE829 HORIZON study in APOL1-mediated kidney disease, with data forecast for early 2027. This is unrelated to pelacarsen’s HORIZON trial. [Full notes](../topics/17_kidney.md#note-2026-11-10-mze829-horizon-enrollment-complete).
- **2026-11-10 — Oral ecnoglutide registers a separate obesity Phase 2 trial.** New trial-registry protocol; no results. A newly registered oral-ecnoglutide trial will measure 24-week weight change in Chinese adults; the oral formulation is separate from injectable ecnoglutide evidence. [Full notes](../topics/03_glp1.md#note-2026-11-10-oral-ecnoglutide-phase2-registration).
- **2026-11-09 — Mazdutide’s TIMES protocol separates glucose control from coronary-plaque imaging.** New randomized protocol; no clinical-event result. A type 1 diabetes study plans CGM outcomes at 16 weeks and CCTA plaque measures at 52 weeks. The title’s cardiovascular-protection wording is not evidence of fewer heart attacks. [Full notes](../topics/03_glp1.md#note-2026-11-10-mazdutide-times-type1-protocol).
- **2026-11-08 — CIDEB silencing adds 36-week liver-fat results.** Sponsor numerical account with simultaneous paper publication; full paper not appraised. A small first-human CIDEB-siRNA report shows durable liver-fat reductions, with no proof yet of fibrosis reversal or fewer clinical liver events. [Full notes](../topics/13_liver.md#note-2026-11-10-cideb-sirna-week36-report).
- **2026-11-10 — SCREEN Yourself will test screening completion after mailed self-sampling.** New randomized screening-delivery protocol; no results. A new 852-person study will compare mailed FIT/HPV self-sampling with usual practice, measuring completion and diagnostic resolution rather than test accuracy or mortality. [Full notes](../topics/02_galleri.md#note-2026-11-10-screen-self-sampling-rct).
- **2026-10-28 — Baseline: portable ultrasound can triage abnormal breast examinations.** Newly appraised prospective human study; October publication, not new November trial. In a selected 319-person study, ultrasound by trained non-radiologists helped triage abnormal clinical breast examinations. This does not establish a replacement for population mammography or improved survival. **Recovered baseline/context; not breaking news.** [Full notes](../topics/02_galleri.md#note-2026-11-10-portable-ultrasound-cbe-india-baseline).
- **2026-11-09 — BRIDGES-NBS moves toward enrollment in Oregon.** Laboratory-partner enrollment announcement; no clinical-outcome results. GeneDx reports Oregon enrollment activity in the multi-state newborn-genomic-screening study. Enrollment and feasibility remain separate from demonstrated long-term benefit. [Full notes](../topics/28_genetic_screening.md#note-2026-11-10-bridges-nbs-oregon-enrollment).
- **2026-11-09 — PIKTOR plus paclitaxel reports an early response signal with substantial harms.** Sponsor-only uncontrolled Phase 2 topline. The PIK-201 report shows responses in selected previously treated endometrial cancers, but has no randomized comparator and reports grade 3-or-higher treatment-related harms in 64%. [Full notes](../topics/14_cancer_vaccines.md#note-2026-11-10-piktor-pik201-topline).
- **2026-11-09 — Two Phase 3 protocols expand EGFR-ADC plus checkpoint research.** New trial-registry protocols; no outcomes. New SYS6010/enlonstobart studies address postoperative recurrence and recurrent/metastatic disease in distinct cancer populations, with no clinical results yet. [Full notes](../topics/14_cancer_vaccines.md#note-2026-11-10-sys6010-enlonstobart-phase3-protocols).
- **2026-11-02 — Recovered lead: sponsor reports a first human senolytic-immunotherapy dose.** Sponsor-only first-dose claim; public protocol and oversight not verified. Immorta Bio reports a first SenoMune-0257 dose in an advanced-cancer patient in Mexico, with no disclosed human efficacy/safety results or verified registry protocol. **Recovered baseline/context; not breaking news.** [Full notes](../topics/05_longevity.md#note-2026-11-10-senomune-first-human-claimed-baseline).
- **2026-11-10 — TARBELA-AD is recruiting for an oral neuroinflammation approach.** Registry recruitment update and sponsor CTAD program; no efficacy readout. Roche identifies RG6434 as the NLRP3 inhibitor in TARBELA-AD (RO7568282). The 450-person Phase 2 registry now lists recruitment, with 72-week cognitive/function outcomes planned. CTAD will separately cover early safety, trontinemab biomarkers, prevention-trial design and diagnostics. [Full notes](../topics/08_alzheimers.md#note-2026-11-10-tarbela-ad-recruitment-and-ctad).
- **2026-11-09 — Compass completes the COMP360 psilocybin application.** Sponsor-reported completed U.S. submission; regulatory decision pending. Compass says the final COMP360 NDA for treatment-resistant depression is submitted, fulfilling its November 3 forecast. FDA filing acceptance, a product-specific decision date, approval and access are separate and unverified. [Full notes](../topics/09_psychedelics.md#note-2026-11-10-comp360-final-nda-submission).
- **2026-11-09 — Early DT402 autism pilot prompts a planned dose study.** Sponsor-only exploratory Phase 2a report; uncontrolled five-person study. Definium describes exploratory functional and social measures after one dose of R(-)-MDMA in five autistic adults. The open-label pilot cannot establish efficacy; a multiple-dosing study is forecast for 2027. [Full notes](../topics/09_psychedelics.md#note-2026-11-10-dt402-asd-phase2a-five-person-report).
- **2026-11-06 — Small MDMA-assisted therapy trial reports social anxiety improvement.** Peer-reviewed randomized open-label waitlist comparison; primary abstract appraised. In 20 adults with social anxiety disorder, MDMA-assisted therapy improved the week-16 Liebowitz score versus waitlist by 43.3 points (95% CI 29.5–57.1 in favor of treatment). The comparison cannot isolate the drug from therapy and expectancy. [Full notes](../topics/09_psychedelics.md#note-2026-11-10-mdma-social-anxiety-waitlist-publication).
- **2026-11-10 — Second Caplyta trial reports improved acute bipolar mania symptoms.** Sponsor-reported randomized Phase 3 result presented at NEI; full poster unappraised. At three weeks, Study 452 reports a 3.7-point greater mania-score reduction with lumateperone than placebo; 43.9% versus 23.7% had at least a 50% symptom-score reduction. J&J plans a U.S. submission, and acute mania remains unapproved. [Full notes](../topics/10_ssri_antidepressants.md#note-2026-11-10-caplyta-study452-bipolar-mania).
- **2026-11-10 — Brenipatide is registered as an add-on for partially responsive depression.** New randomized Phase 2 registry protocol; no outcomes. RENEW-MDD-3 will test the dual GIP/GLP-1 agonist brenipatide versus placebo alongside a stable antidepressant in 330 adults. The primary endpoint is depression symptoms at week 10; recruitment and benefit are not yet established. [Full notes](../topics/10_ssri_antidepressants.md#note-2026-11-10-brenipatide-renew-mdd3-phase2-registration).
- **2026-11-09 — ReBUILD registers a topical dry-AMD trial.** New randomized Phase 2/3 trial protocol; no results. A 300-person trial will compare two strengths of daily bevemipretide eye drops with vehicle in extrafoveal geographic atrophy. Its primary outcome is structural photoreceptor loss, not proven vision preservation. [Full notes](../topics/18_hearing_vision.md#note-2026-11-10-bevemipretide-rebuild-dry-amd-registration).
- **2026-11-04 — Idorsia reports pediatric daridorexant breakthrough designation.** Newly recovered November 4 sponsor-reported FDA designation; not approval. Idorsia says FDA granted Breakthrough Therapy Designation for insomnia ages 10 to under 18. The previously reported short Phase 2 evidence is unchanged; pediatric Phase 3 remains forecast for H2 2027. [Full notes](../topics/29_sleep_insomnia.md#note-2026-11-10-daridorexant-pediatric-breakthrough).
- **2026-11-05 — DARI-DREAM records recruitment and an October start.** Newly recovered November 5 Phase 3 registry update; no efficacy readout. The adult daridorexant daytime-function study now records recruitment and an October 28 actual start. Sleep-diary total sleep time is primary; daytime function is secondary. No new U.S. label claim is established. [Full notes](../topics/29_sleep_insomnia.md#note-2026-11-10-dari-dream-recruiting-start).
- **2026-11-06 — Monthly berobenatide OSA trial is now recruiting without PAP.** Newly recovered November 6 Phase 3 recruitment update; no results. The VESPER-OSA2 registry now lists recruitment and an actual October 19 start for the non-PAP cohort with overweight or obesity. Its 52-week apnea index endpoint is not evidence of a cardiovascular benefit or PAP replacement. [Full notes](../topics/30_sleep_apnea.md#note-2026-11-10-vesper-osa2-recruiting-registry).
- **2026-11-09 — Oveporexton Schedule IV rule is set for November 12 publication.** DEA interim final rule on public inspection; publication and effective date pending. The DEA rule was filed November 9 and is scheduled to publish and take effect November 12. It puts Orzeyful in Schedule IV. This is a U.S. access milestone after August approval for adult narcolepsy type 1, not confirmation of pharmacy supply or insurer coverage. [Full notes](../topics/31_sleep_hypersomnolence.md#note-2026-11-10-oveporexton-dea-schedule-iv-public-inspection).
- **2026-11-09 — Enobosarm’s next report targets physical function in an older subgroup.** Dated sponsor conference announcement; no new numerical result. Veru schedules a November 16 post-hoc QUALITY physical-function analysis in adults aged 65 or older; no new effect size or harms table is disclosed. [Full notes](../topics/04_muscle.md#note-2026-11-10-enobosarm-obesityweek-2026-function-schedule).
- **2026-11-10 — Scholar Rock confirms SMA infusions and separates SRK-439 data generation from disclosure.** Sponsor access/status update and forecasts; no new efficacy readout. The sponsor confirms first commercial Isembyld infusions in October and forecasts Q1 2027 public SRK-439 data, distinct from having topline data by year-end 2026. [Full notes](../topics/04_muscle.md#note-2026-11-10-scholarrock-sma-access-srk439-timing).
- **2026-11-09 — COMPACT separates thigh-muscle preservation from strength during incretin treatment.** New randomized supportive-care protocol; no results. A new 94-person randomized trial will test exercise plus protein during semaglutide/tirzepatide treatment, measuring MRI muscle volume separately from strength and function. [Full notes](../topics/04_muscle.md#note-2026-11-10-compact-glp1-exercise-protein-registration).
- **2026-11-10 — ACR abstracts add dose-specific knee-pain estimates, with a safety-table gap.** Original Phase 3 conference abstracts newly appraised; earlier toplines/publication already known. ACR abstracts quantify WOMAC pain changes in TRIUMPH-4 and the 574-person TRIUMPH-1-OA substudy, preserving efficacy estimands. These are symptom/function findings, not cartilage repair. [Full notes](../topics/11_joint_preservation.md#note-2026-11-10-retatrutide-acr2026-oa-abstracts-appraised).
- **2026-11-09 — PRECISION will test local iloprost for high-risk fracture healing.** New randomized Phase 2 protocol; no results. PRECISION plans 60 patients and separates CT-defined bone healing from pain, function and return to work; no clinical benefit is established. [Full notes](../topics/11_joint_preservation.md#note-2026-11-10-precision-iloprost-fracture-registration).
- **2026-11-09 — NVD003’s registry replaces an elapsed completion estimate.** Registry timing change; no results; excluded from medical-news alerts. The NVD003 pediatric pivotal record now estimates primary/final completion in June 2032. The explanation is unverified; the timing change is not evidence of failed healing. **Administrative timing correction; no new clinical result.** [Full notes](../topics/11_joint_preservation.md#note-2026-11-10-nvd003-completion-estimate-2032).
- **2026-11-09 — ALLO-329 reports early scleroderma activity with conditioning-specific harms.** Sponsor-reported preliminary uncontrolled Phase 1 data. ALLO-329 reports skin-score responses in 8/10 selected scleroderma patients; safety includes serious treatment-emergent events in 6/18. Small nonrandomized conditioning cohorts cannot establish cure or a safety advantage. [Full notes](../topics/15_autoimmune.md#note-2026-11-10-allo329-resolution-18patient-firstdata).
- **2026-11-09 — NKX019 adds small myositis and scleroderma cohorts, with conditioning and retreatment caveats.** Sponsor-reported preliminary uncontrolled Phase 1/2 CAR-NK results. NKX019 shows early disease-specific responses in small high-dose subsets. Pooled 40-person safety and limited follow-up do not establish comparative safety or durable remission. [Full notes](../topics/15_autoimmune.md#note-2026-11-10-nkx019-ntrust-acr-initial-myositis-ssc).
- **2026-11-09 — KYSA-8’s paper adds uncertainty and important harms to the existing SPS cohort.** Peer-reviewed single-arm Phase 2 primary analysis; same cohort, earlier cutoff. The KYSA-8 paper adds a 16-week walking-time confidence interval and detailed CRS, ICANS, neutropenia and serious-event descriptions. This is the same 26-person cohort, not independent replication. [Full notes](../topics/15_autoimmune.md#note-2026-11-10-mivcel-sps-jama-primaryanalysis-harms).
- **2026-11-10 — TOGETHER-PsA’s original abstract adds analysis details and uncertainty.** Original conference abstract newly appraised; previously announced efficacy, exploratory week 52. TOGETHER-PsA’s original abstract adds analysis-arm counts of 138/133 and an ACR50 difference of 28.0 percentage points (95% CI 17.1–38.9). Week 52 remains exploratory; matched numeric harms remain missing. [Full notes](../topics/15_autoimmune.md#note-2026-11-10-together-psa-week52-originalabstract-ci).
- **2026-11-09 — Alenura reports acute bladder-pain benefit, with magnitude and harms still missing.** Sponsor-reported randomized Phase 2 topline. Alenura’s 153-person Phase 2 sponsor report claims superiority over placebo and each component for 12-hour acute bladder-pain relief; effect sizes, confidence intervals and comparative harms remain undisclosed. [Full notes](../topics/16_pain.md#note-2026-11-10-alenura-phase2-bladderspain-topline).
- **2026-11-10 — A small suzetrigine knee-replacement study prioritizes feasibility.** New randomized Phase 4 pilot protocol; no results. A 40-person open-label knee-replacement trial adds suzetrigine to multimodal care. Primary endpoints concern feasibility; opioid use and pain are separate outcomes. [Full notes](../topics/16_pain.md#note-2026-11-10-suzetrigine-tka-feasibility-pilot-registration).
- **2026-11-10 — HNK’s experimental-pain start estimate moves to November 15.** Administrative registry timing update; excluded from alerts. NIH’s experimental HNK study now has a November 15 estimated start; it remains not yet recruiting, with no result or first dose confirmed. **Administrative timing correction; no new clinical result.** [Full notes](../topics/16_pain.md#note-2026-11-10-hnk-start-estimate-nov15).
- **2026-11-09 — Shigella vaccine reports adult challenge success, with infant antibody data.** Sponsor-only Phase 2 topline; effect magnitude undisclosed. Valneva reports success on a Phase 2 adult Shigella challenge endpoint without effect magnitude or detailed harms. Separate infant antibody findings do not demonstrate protection. [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-s4v2-shigella-phase2-topline).
- **2026-11-10 — IXCHIQ reports five-year antibodies while U.S. use remains discontinued.** Sponsor-only long-term antibody follow-up; historical FDA safety and access context. Valneva reports a 94% five-year antibody response in 221 evaluable adults. This does not establish clinical efficacy; the live vaccine’s earlier U.S. safety suspension and discontinuation remain distinct. [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-ixchiq-fiveyear-antibodies-us-status).
- **2026-11-09 — Newly tracked long-acting anti-TSLP program separates early signals from exacerbation outcomes.** Recovered human-program baseline and dated sponsor filing; earlier initiation dates retained. A November 9 filing adds WIN378 as a tracked asthma/COPD program. Earlier FEV1 and FeNO findings do not establish exacerbation benefit; sponsor/registry phase and enrollment descriptions differ. **Recovered baseline/context; not breaking news.** [Full notes](../topics/26_allergy_airway.md#note-2026-11-10-win378-human-program-baseline).
- **2026-09-26 — Antibody–antibiotic conjugate full report highlights infusion-reaction limits.** Recovered peer-reviewed Phase 1b full publication; old completed trial, not November readout. A recovered September full paper identifies infusion-reaction and exposure limitations with DSTA4637S. Further S. aureus bacteremia development is not planned. **Recovered baseline/context; not breaking news.** [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-dsta4637s-recovered-full-paper).
- **2026-09-29 — Once-daily ertapenem–zidebactam remains early safety/PK research.** Recovered peer-reviewed Phase 1 full publication; healthy volunteers only. A recovered September healthy-volunteer paper adds detailed safety/PK findings for ertapenem–zidebactam, including an unresolved ECG observation. Patient infection efficacy remains unproven. **Recovered baseline/context; not breaking news.** [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-wck6777-recovered-phase1-paper).
- **2026-11-08 — ECLIPSE1 meets its prespecified hepatitis-delta virologic endpoint.** Sponsor-only randomized open-label Phase 3 topline and conference report. ECLIPSE 1 reports 44% versus 0% viral/liver-lab composite response, comparing active week 48 with delayed-treatment week 12. This is a Phase 3 sponsor topline, not a cure or clinical-outcome result. [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-eclipse1-hdv-phase3-topline).
- **2026-11-08 — SOLSTICE adds selected long-term suppression and early off-treatment observations.** Sponsor-only Phase 2 extension and exploratory nonrandomized withdrawal snapshot. SOLSTICE reports viral suppression in all 28 week-96 completers and early off-treatment results in 10 selected patients. Unequal follow-up and incomplete flare assessment preclude a cure claim. [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-solstice-week96-withdrawal).
- **2026-11-05 — HBV gene editing adds biopsy and pgRNA evidence, without proving cure.** Sponsor-only Phase 1 interim biomarker and safety update. PBGENE-HBV reports undetectable pgRNA in 11/12 evaluable patients and paired biopsies in two. The Phase 1 biomarker findings do not establish cure or long-term safety. [Full notes](../topics/27_infectious_disease.md#note-2026-11-10-pbgene-hbv-aasld-biomarkers).
- **2026-11-10 — SNT-9465 recruitment pauses for a local-tolerability review.** Sponsor safety/development update. Syntara paused Phase 1b SNT-9465 recruitment after blinded reports of mild-to-moderate skin irritation. Counts and treatment assignment are undisclosed. Unblinded review is expected Q4 2026 before restart or discontinuation; the prior Q1 2027 topline forecast is conditional. [Full notes](../topics/21_scars.md#note-2026-11-10-snt9465-recruitment-pause).
- **2026-11-09 — VDPHL01 reports further hair gains through 12 months, without a continuing placebo group.** Sponsor-reported Phase 2/3 extension results. Sponsor-reported month-12 gains were 29.7/43.9 non-vellus hairs/cm² for continuing once-/twice-daily groups; improved/much-improved patient ratings were 48.4%/68.0%. The 421-person extension includes placebo crossover, leaving no continuing month-12 placebo and no standard-minoxidil head-to-head. Outcome-specific observed-data denominators remain incomplete. [Full notes](../topics/19_hair_loss.md#note-2026-11-10-vdphl01-study302-twelve-month).
- **2026-11-06 — Baseline recovery: two Brazilian oral-minoxidil Phase 3 programs plan 2027 starts.** Historical program baseline; November registry updates, no results. Recovered historical N1087 oral-minoxidil Phase 3 records each plan 372 participants versus placebo. November updates still show not yet recruiting, January 2027 estimated starts and 2028 completion; no results or head-to-head comparison with standard topical therapy. **Recovered baseline/context; not breaking news.** [Full notes](../topics/19_hair_loss.md#note-2026-11-10-n1087-minora-historical-programs).
- **2026-11-08 — Two uncontrolled GLP-1 cohorts report better facial-appearance satisfaction.** Sponsor conference reporting; open-label Phase 4 cohorts. Sponsor-reported GLP-1 cohorts improved FACE-Q facial satisfaction by 42.4 points (HARMONY, 30 participants) and 39.6 points (HALO interim 25/75). Open-label single-arm design, short follow-up and incomplete harms prevent claims of comparative benefit or biological fat regeneration. [Full notes](../topics/22_facial_volume.md#note-2026-11-10-glp1-halo-harmony-sponsor-results).
- **2026-11-04 — A randomized temple-filler study shows a six-month appearance benefit.** Peer-reviewed randomized study; full paper appraised. Specific Novapath temple PLLA improved blinded six-month appearance ratings versus no treatment (80.2% vs 1.8%; 162 randomized). Local reactions were frequent; controls crossed after six months. It does not establish superiority to other fillers, native fat restoration or long-term comparative durability. [Full notes](../topics/22_facial_volume.md#note-2026-11-10-temple-plla-randomized-paper).
- **2026-11-05 — A skin-quality injection trial reports short-term benefit versus no treatment.** Peer-reviewed randomized study; full paper appraised. A 446-person randomized hyamax injection study favored treatment on a short-term composite appearance response versus no intervention (84.9% vs 14.1%). Unblinded participants, no procedure control, more overall adverse events and limited comparative follow-up constrain interpretation. [Full notes](../topics/20_skin_aging.md#note-2026-11-10-hyamax-skin-quality-randomized-paper).
- **2026-10-13 — Recovered registry identifies the trenibotE–onabotulinumtoxinA combination study.** October Phase 2 registration recovered; November status verified. Recovered October Phase 2 registry corroborates the trenibotE/onabotulinumtoxinA combination study and actual October 8 start: 300 planned, recruiting, June 2028 completion estimated. No results; separate U.S. monotherapy resubmission/decision timing remains a management forecast. **Recovered baseline/context; not breaking news.** [Full notes](../topics/20_skin_aging.md#note-2026-11-10-treni-onabot-combination-registry).
- **2026-11-06 — A four-person pilot proposes testing whether trenibotE shortens another toxin’s effect.** New exploratory registry protocol; no results. A not-yet-recruiting four-person split-face pilot proposes testing whether trenibotE shortens onabotulinumtoxinA effects. No outcomes; design placeholders and incompatible estimated start/completion dates prevent a reliable readout forecast or reversal claim. [Full notes](../topics/20_skin_aging.md#note-2026-11-10-treni-reversal-pilot-registration).
- **2026-11-10 — GR2301 adds another anti-IL-15 vitiligo program.** New randomized Phase 2 registry protocol; no results. New GR2301 anti-IL-15 Phase 2 registry plans 120 participants, three dose groups and placebo, with week 24 F-VASI50 primary. Not yet recruiting; November 2026 start and May 2028 primary completion estimated. No efficacy, safety or U.S. approval established. [Full notes](../topics/23_pigmentation.md#note-2026-11-10-gr2301-grevit2-registration).
- **2026-11-05 — Sham-controlled laser trial finds no root protection or faster alignment.** Peer-reviewed randomized trial; original abstract appraised. A 40-person sham-controlled laser trial found no root-resorption protection or faster alignment (123.8 vs 126.2 days), despite short-term pain improvement. Two tooth/time comparisons favored sham for resorption; small sample and multiple comparisons limit harm inference. Full paper and harms remain gaps. [Full notes](../topics/25_dental.md#note-2026-11-10-laser-orthodontic-root-resorption-rct).
- **2026-11-09 — Late registration adds a human-wear study of printed aligner materials.** Retrospective registration of a completed materials study; no results. Late registration of a completed 12-person human-wear study compares printed TC-85/TA-28 aligner materials after two weeks. No results or tooth-movement outcomes; it cannot establish faster alignment, root safety, retention or comparative biocompatibility. **Recovered baseline/context; not breaking news.** [Full notes](../topics/25_dental.md#note-2026-11-10-printed-aligner-intraoral-aging-registry).
- **2026-11-09 — Baseline recovery: tesamorelin is being studied after peripheral nerve repair.** Historical Phase 2 program; November registry update, no results. Recovered 2017-registered tesamorelin nerve-repair Phase 2 study remains recruiting with 36 planned and December 2027 completion estimated. Pinch strength and hand/nerve function are endpoints; no fat-removal results. Masking conflicts with the untreated comparator remain unresolved. **Recovered baseline/context; not breaking news.** [Full notes](../topics/06_localized_fat.md#note-2026-11-10-tesamorelin-nerve-recovery-historical-baseline).

## Coverage by active topic

### Whole-body MRI

[Topic](../topics/01_whole_body_mri.md)

**Formal coverage:** Registry discovery September 5–November 10: 161/161 records over 2 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete.; HERCULES registry access recovered; its April 30, 2025 update still lists recruiting and January 2034/January 2037 estimates, with no results. These are old estimates, not a new readout..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28whole+body+MRI+screening+OR+whole-body+MRI+screening+OR+HERCULES%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc).

### Galleri and organ-specific cancer screening

[Topic](../topics/02_galleri.md)

**Formal coverage:** Registry discovery September 5–November 10: 1056/1056 records over 11 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28multi-cancer+detection+OR+cancer+screening+blood+OR+colorectal+screening+OR+breast+screening%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/study/NCT07927686); [Source 3](https://ascopubs.org/doi/10.1200/GO-26-00354); [Source 4](https://www.iarc.who.int/wp-content/uploads/2026/11/pr388_E.pdf).

### GLP-1 and related metabolic therapies

[Topic](../topics/03_glp1.md)

**Formal coverage:** Registry discovery September 5–November 10: 480/480 records over 5 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28GLP-1+OR+incretin+OR+retatrutide+OR+tirzepatide+OR+semaglutide+OR+amylin+OR+eloralintide+OR+zenagamtide%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/study/NCT07929298); [Source 3](https://clinicaltrials.gov/study/NCT07924553).

### Muscle building and preservation

[Topic](../topics/04_muscle.md)

**Formal coverage:** Reviewed full saved topic corpus and current scope/state; 56/56 ClinicalTrials.gov discovery records across 1 page for November 3–10 retrieved, plus all saved named IDs within 76/76 combined records across four topics. Targeted sponsor/primary searches prioritized new enobosarm function announcement, Scholar Rock access/timing, and COMPACT protocol. Full literature and earlier September 5–November 2 discovery reappraisal not completed.

**Informal coverage:** Targeted Reddit, Cantor transcript and sponsor-source searches revisited the saved enobosarm Phase3-scale planning claim. New November 9 release still describes separate Phase 2b PLATEAU; noactual4,500-person Phase 3registration/start confirmed. Original complete Cantor audio not appraised.

**Remaining gaps:** focused_incomplete; complete worldwide papers/supplements, non-US registries, regulator-label/hold census, original conference recordings and long-form informal-source appraisal remain incomplete. Full-success timestamps and baseline flags must remain unchanged.; Full COURAGE manuscript, complete BELIEVE withdrawal/function tables and amended taldefgrobep partner/dose remain incompletely appraised. Enobosarm scheduled subgroup numerics/harms remain unavailable..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://ir.verupharma.com/news-events/press-releases/detail/263/veru-to-present-new-results-on-effects-of-enobosarm-on); [Source 2](https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-third-quarter-2026-financial-results-and/); [Source 3](https://www.sec.gov/Archives/edgar/data/1727196/000119312526454434/srrk-20260930.htm); [Source 4](https://clinicaltrials.gov/study/NCT07926152); [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+sarcopenia+OR+%22lean+body+mass%22+OR+enobosarm+OR+apitegromab+OR+bimagrumab+OR+taldefgrobep%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-11-03%2C2026-11-10%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true).

### Longevity and healthspan trials

[Topic](../topics/05_longevity.md)

**Formal coverage:** Registry discovery September 5–November 10: 39/39 records over 1 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28healthspan+OR+geroscience+OR+senolytic+OR+aging+metformin+OR+aging+rapamycin%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://www.prnewswire.com/news-releases/first-human-administration-of-senolytic-immunotherapy-to-fight-cellular-aging-announced-by-immorta-bio-302926449.html).

### Localized fat removal and cellulite

[Topic](../topics/06_localized_fat.md)

**Formal coverage:** Twenty-one named records, 24 recent registry records and six paper-search records retrieved; the broader registry query timed out. Existing CBL-514 SUPREME sponsor/registry recruitment discrepancies, RZL-012 China filing forecast and small cellulite datasets remain unresolved or already recorded. No new selected fat-removal efficacy result. Tesamorelin nerve recovery is a recovered historical indication lead, not a new fat result; the TRIUMPH frailty study remains separate. Complete international registry, metabolic outcomes and device/procedure appraisal remain gaps.

**Informal coverage:** Searched indexed CBL-514/RZL-012/tesamorelin Reddit and podcast/talk leads. Confounded before/after anecdotes and unverified supply claims provide no new formal efficacy or access evidence. Podcast descriptions were not full recordings; no selected new specific rumor.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Twenty-one named records, 24 recent registry records and six paper-search records retrieved; the broader registry query timed out. Existing CBL-514 SUPREME sponsor/registry recruitment discrepancies, RZL-012 China filing forecast and small cellulite datasets remain unresolved or already recorded. No new selected fat-removal efficacy result. Tesamorelin nerve recovery is a recovered historical indication lead, not a new fat result; the TRIUMPH frailty study remains separate. Complete international registry, metabolic outcomes and device/procedure appraisal remain gaps.; Searched indexed CBL-514/RZL-012/tesamorelin Reddit and podcast/talk leads. Confounded before/after anecdotes and unverified supply claims provide no new formal efficacy or access evidence. Podcast descriptions were not full recordings; no selected new specific rumor..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/study/NCT03150511); [Source 2](https://www.podparadise.com/Podcast/1840105648); [Source 3](https://angioskope.com.br/canal/).

### Broad cardiovascular prevention, lipids and screening

[Topic](../topics/07_cardiovascular.md)

**Formal coverage:** Registry discovery September 5–November 10: 976/976 records over 10 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28lipoprotein+OR+lipid+lowering+OR+PCSK9+OR+VERVE+OR+coronary+calcium+OR+coronary+plaque+OR+ziltivekimab%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://fhef.org/wp-content/uploads/FA-11803517_Pelacarsen_Patient-Community-Statement-2026-1.pdf); [Source 3](https://fhef.org/news/lpahorizon-fh-europe-foundation-shares-novartis-patient-community-statement/); [Source 4](https://clinicaltrials.gov/study/NCT05900141); [Source 5](https://clinicaltrials.gov/study/NCT07839936); [Source 6](https://newsroom.heart.org/news/researchers-say-inflammation-as-a-treatment-target-still-important-despite-neutral-results-of-zeus-trial); [Source 7](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587).

### Alzheimer's screening and therapies

[Topic](../topics/08_alzheimers.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 467/467 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 23 saved named records. Europe PMC returned 644/644 publication records for 2026-09-05 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Reconciled TARBELA-AD sponsor alias and recruitment; current PrevenTRON registry and CTAD program checked. Reviewed selected clinical/diagnostic publication abstracts, including new MCI digital-screening work.

**Informal coverage:** Reopened original Longo transcript and Attia/Davidson chapter notes; sampled CTAD and prevention-focused Reddit/talk queries. No selected new attributable development rumor. Paid Attia transcript remains inaccessible.

**Remaining gaps:** CTAD sessions have not occurred; Alzheon announcement was located but ORION-E4 start timing and original detailed subgroup results were not fully reconciled; no preventive efficacy inferred.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28Alzheimer+OR+%22mild+cognitive+impairment%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT03069014%2CNCT03887455%2CNCT04437511%2CNCT04468659%2CNCT04619420%2CNCT04639050%2CNCT05026866%2CNCT05399888%2CNCT06246019%2CNCT06335173%2CNCT06957418%2CNCT06996730%2CNCT07169578%2CNCT07169630%2CNCT07170150%2CNCT07214727%2CNCT07688213%2CNCT07794670%2CNCT07827768%2CNCT07869238%2CNCT07883291%2CNCT07905352%2CNCT07911826&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28Alzheimer+OR+%22mild+cognitive+impairment%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://www.ctad-alzheimer.com/sites/www.ctad-alzheimer.com/files/medias/documents/Final_Program_CTAD26_06112026%20%281%29.pdf); [Source 5](https://alzheon.com/wp-content/uploads/2026/11/2026-CTAD-Conference-Press-Release-06NOV2026-FINAL.pdf); [Source 6](https://pubmed.ncbi.nlm.nih.gov/42981698/); [Source 7](https://www.roche.com/investors/updates/inv-update-2026-11-10); [Source 8](https://www.gene.com/media/press-releases/15142/2026-11-09/genentech-and-roche-present-new-data-acr); [Source 9](https://clinicaltrials.gov/study/NCT07781657); [Source 10](https://clinicaltrials.gov/study/NCT07717411); [Source 11](https://www.usagainstalzheimers.org/brainstorm/beyond-amyloid-why-protecting-synapses-could-change-alzheimers-prevention-dr-frank-longo); [Source 12](https://clinicaltrials.gov/study/NCT03069014); [Source 13](https://peterattiamd.com/michaeldavidson/); [Source 14](https://clinicaltrials.gov/study/NCT07794670).

### Psilocybin and related therapies

[Topic](../topics/09_psychedelics.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 132/132 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 21 saved named records. Europe PMC returned 226/226 publication records for 2026-09-05 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Appraised Compass completed filing, Definium November 9 development disclosure and social-anxiety MDMA primary abstract. Deduplicated earlier DT120 GAD toplines; public Usona pages checked.

**Informal coverage:** Reopened saved Usona, Doblin and COMP360 original/secondhand sources; sampled November 9 Reddit weekly and Compass filing threads. Commentary largely repeats the official filing or the same anonymous Usona chain. No new independent corroboration.

**Remaining gaps:** Full NEI posters, underlying MDMA manuscript, DT402 numerical tables, Usona original application and FDA acceptance notices unavailable or incomplete.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28psilocybin+OR+LSD+OR+MDMA+OR+ibogaine+OR+DMT+OR+methylone+OR+mebufotenin+OR+CYB003%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT05029466%2CNCT05065294%2CNCT05741710%2CNCT05800860%2CNCT05870540%2CNCT06215261%2CNCT06308653%2CNCT06524830%2CNCT06564818%2CNCT06809595%2CNCT07456696%2CNCT07818720%2CNCT07820033%2CNCT07833761%2CNCT07836647%2CNCT07852832%2CNCT07871877%2CNCT07877987%2CNCT07895134%2CNCT07909408%2CNCT07920081&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28psilocybin+OR+LSD+OR+MDMA+OR+ibogaine+OR+DMT+OR+methylone+OR+mebufotenin+OR+CYB003%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-453626/dftx-20260930.htm); [Source 5](https://www.usonainstitute.org/psilocybin/); [Source 6](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [Source 7](https://www.fda.gov/CNPV); [Source 8](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights); [Source 9](https://pubmed.ncbi.nlm.nih.gov/42994762/); [Source 10](https://clinicaltrials.gov/study/NCT05138068); [Source 11](https://www.reddit.com/r/shroomstocks/comments/1xrr3g3/rshroomstocks_weekly_discussion_thread_november/); [Source 12](https://www.reddit.com/r/shroomstocks/comments/1xrpciy/compass_pathways_completes_comp360_psilocybin_new/); [Source 13](https://psychedelicalpha.com/news/usona-files-psilocybin-for-depression-nda-as-race-with-compass-tightens/); [Source 14](https://www.reddit.com/r/Cmpsstock/comments/1x40vdv/fda_nda_and_cnpv_timelines_to_approval/); [Source 15](https://www.reddit.com/r/shroomstocks/comments/1xdpxki/exclusive_mdmaassisted_therapy_could_get_fda/); [Source 16](https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/).

### Mental-health treatments, SSRIs and newer antidepressants

[Topic](../topics/10_ssri_antidepressants.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 3692/3692 records across 4 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 31 saved named records. Europe PMC returned 299/299 publication records for 2026-11-03 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Appraised Study 452 release/registry and RENEW-MDD-3 protocol. Sampled primary abstracts for ketamine+iTBS, lumateperone post-hoc MDD evidence, addiction and newer modalities.

**Informal coverage:** Targeted Reddit, congress-slide and sponsor-call searches sampled depression, bipolar mania and experimental adjuncts. No distinct verified-origin new rumor selected. Complete discussion and original Q&A/audio appraisal remains open.

**Remaining gaps:** Complete Study 452 poster/CIs/safety denominators, postpartum-esketamine article without abstract and comprehensive true-SSRI/mental-health appraisal remain missing.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; The larger literature download was incomplete; the November 3–10 Europe PMC fallback was retrieved and screened, while earlier new-to-notebook items remain incompletely appraised..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28depression+OR+antidepressant+OR+bipolar+OR+PTSD+OR+obsessive-compulsive+OR+addiction+OR+schizophrenia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28depression+OR+antidepressant+OR+bipolar+OR+PTSD+OR+obsessive-compulsive+OR+addiction+OR+schizophrenia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc&pageToken=ZVNj7o2Elu8o3lpyXdC5577umpOQJJxuYvim3fAfmj6SuP08FCfCF_fU8tFH0yI); [Source 3](https://clinicaltrials.gov/api/v2/studies?query.term=%28depression+OR+antidepressant+OR+bipolar+OR+PTSD+OR+obsessive-compulsive+OR+addiction+OR+schizophrenia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc&pageToken=ZVNj7o2Elu8o3lpyXdC5577umpOQJJxuYvik2fQenD6SuP08FCfCFPTR9dJP1SI); [Source 4](https://clinicaltrials.gov/api/v2/studies?query.term=%28depression+OR+antidepressant+OR+bipolar+OR+PTSD+OR+obsessive-compulsive+OR+addiction+OR+schizophrenia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc&pageToken=ZVNj7o2Elu8o3lpyXdC5577umpOQJJxuYvms1fASlD6SuP08FCfCF_PQ9dNG0SI); [Source 5](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT02978326%2CNCT04019704%2CNCT04138680%2CNCT04442503%2CNCT04599855%2CNCT04985942%2CNCT05113771%2CNCT05147142%2CNCT05693935%2CNCT05895643%2CNCT05966155%2CNCT06215261%2CNCT06462586%2CNCT06785012%2CNCT07218354%2CNCT07393919%2CNCT07810738%2CNCT07824206%2CNCT07824973%2CNCT07839338%2CNCT07857122%2CNCT07857629%2CNCT07868536%2CNCT07880340%2CNCT07887633%2CNCT07892885%2CNCT07901179%2CNCT07908563%2CNCT07909408%2CNCT07911787%2CNCT07918222&pageSize=1000&format=json); [Source 6](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28depression+OR+antidepressant+OR+bipolar+OR+PTSD+OR+obsessive-compulsive+OR+addiction+OR+schizophrenia%29+AND+FIRST_PDATE%3A%5B2026-11-03+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 7](https://pubmed.ncbi.nlm.nih.gov/42983941/); [Source 8](https://pubmed.ncbi.nlm.nih.gov/42987117/); [Source 9](https://pubmed.ncbi.nlm.nih.gov/42968686/); [Source 10](https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-second-pivotal-phase-3-study); [Source 11](https://clinicaltrials.gov/study/NCT06462612); [Source 12](https://clinicaltrials.gov/study/NCT07928245); [Source 13](https://www.lilly.com/hcp/congresses/psych-2026); [Source 14](https://cdn.neiglobal.com/content/congressfa/2026/pdf-slides/C13_Psychedelics_McIntyre-Slides.pdf).

### Bone health, joint preservation and cartilage repair

[Topic](../topics/11_joint_preservation.md)

**Formal coverage:** Reviewed full saved topic corpus and current scope/state;143/143 ClinicalTrials.gov discovery records across 2 pages for November 3–10 retrieved, plus saved named IDs within 76/76 combined records. Original ACR retatrutide text, iloprost protocol, NVD003 timing and saved TG-C/senolytic records appraised selectively. Full global bone/fracture/cartilage review remains unfinished.

**Informal coverage:** Revisited original E-Daily September 18 TG-C December forecast and current trialregistry; original shareholder recording/new primary sponsor confirmation remain missing. Targeted Reddit/podcast/new cartilage searches selected no distinct source-grounded new claim; incomplete search is not evidence of absence.

**Remaining gaps:** focused_incomplete; complete worldwide papers/supplements, non-US registries, regulator-label/hold census, original conference recordings and long-form informal-source appraisal remain incomplete. Full-success timestamps and baseline flags must remain unchanged.; ACR retatrutide image-only safety tables and full estimand/missing-data details not appraised; no independent delivery observation. TG-C primary timing/companion outcome and senolytic osteoporosis original results remain unresolved. NVD003 June 2032 estimate explanation unverified..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://acrabstracts.org/abstract/retatrutide-once-weekly-for-the-treatment-of-knee-osteoarthritis-pain-and-obesity-results-from-a-68-week-phase-3-randomized-clinical-trial/); [Source 2](https://acrabstracts.org/abstract/three-doses-of-once-weekly-retatrutide-in-adults-with-knee-osteoarthritis-and-obesity-an-80-week-phase-3-randomized-clinical-trial/); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42814954/); [Source 4](https://clinicaltrials.gov/study/NCT07924722); [Source 5](https://clinicaltrials.gov/study/NCT07112443); [Source 6](https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoarthritis+OR+osteoporosis+OR+%22fracture+healing%22+OR+cartilage%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-11-03%2C2026-11-10%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true).

### Liver health and noninvasive assessment

[Topic](../topics/13_liver.md)

**Formal coverage:** Registry discovery September 5–November 10: 306/306 records over 4 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28MASH+OR+metabolic+dysfunction-associated+steatotic+liver+OR+MASLD+OR+liver+fibrosis%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://investor.regeneron.com/news-releases/news-release-details/cideb-sirna-normalizes-liver-fat-and-improves-liver-injury); [Source 3](https://clinicaltrials.gov/study/NCT06836609); [Source 4](https://clinicaltrials.gov/study/NCT07854782).

### Cancer treatment, vaccines and recurrence prevention

[Topic](../topics/14_cancer_vaccines.md)

**Formal coverage:** Registry discovery September 5–November 10: 711/711 records over 8 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28cancer+vaccine+OR+radiopharmaceutical+OR+antibody+drug+conjugate+OR+CAR-T+solid+tumor+OR+cancer+recurrence+vaccine%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://investors.faeththerapeutics.com/static-files/213f58ba-eb92-4149-8a65-517a6df093ef); [Source 3](https://clinicaltrials.gov/study/NCT06463028); [Source 4](https://clinicaltrials.gov/study/NCT07924111); [Source 5](https://clinicaltrials.gov/study/NCT07925021).

### Autoimmune disease and immune reset

[Topic](../topics/15_autoimmune.md)

**Formal coverage:** Reviewed full saved topic corpus and current scope/state;96/96 ClinicalTrials.gov discovery records across 1 page for November 3–10 retrieved, plus saved named IDs within 76/76 combined records. ALLO-329 release, NKX019 SEC data, full KYSA-8 paper/text/table and original TOGETHER-PsA abstract appraised. This is not complete immune-reset, autoimmune-disease or long-term safety appraisal. Targeted restart searches did not establish that new biomarker posters or trial listings resolve prior program-specific safety issues.

**Informal coverage:** Revisited original OncLive September 22 Mehandru/Mount Sinai IBD planning statement plus institutional/registry leads. New cell-therapy cohorts do not confirm that local IBD trial. Targeted Reddit/new cell-therapy and talk searches did not yield a distinct attributable new development claim selected; full audio/Q&A remain unappraised.

**Remaining gaps:** focused_incomplete; complete worldwide papers/supplements, non-US registries, regulator-label/hold census, original conference recordings and long-form informal-source appraisal remain incomplete. Full-success timestamps and baseline flags must remain unchanged.; Miv-cel Table2 versus narrative aggregate grade>=3 treatment-related AE counts conflict; not harmonized. Full supplement and complete ALLO/NKX long-term safety not appraised. No new primary verification of rap-cel/zola-cel restart or Mount Sinai IBD initiation in this focused appraisal. TOGETHER exact matched-arm safety rates missing..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-first-clinical-data-phase-1); [Source 2](https://clinicaltrials.gov/study/NCT07085104); [Source 3](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000027/nktx-20261109.htm); [Source 4](https://clinicaltrials.gov/study/NCT06733935); [Source 5](https://clinicaltrials.gov/study/NCT06557265); [Source 6](https://jamanetwork.com/journals/jamaneurology/fullarticle/2856388); [Source 7](https://clinicaltrials.gov/study/NCT06588491); [Source 8](https://acrabstracts.org/abstract/ixekizumab-plus-tirzepatide-demonstrated-greater-disease-control-at-52-weeks-versus-ixekizumab-alone-with-incremental-improvement-from-week-36-in-adults-with-psoriatic-arthritis-and-overweight-or-obes/); [Source 9](https://clinicaltrials.gov/api/v2/studies?query.term=%28lupus+OR+%22systemic+sclerosis%22+OR+myositis+OR+%22rheumatoid+arthritis%22+OR+%22psoriatic+arthritis%22+OR+%22autoimmune+CAR+T%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-11-03%2C2026-11-10%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true).

### Non-opioid pain treatments

[Topic](../topics/16_pain.md)

**Formal coverage:** Reviewed full saved topic corpus and current scope/state;1,422/1,422 broad ClinicalTrials.gov pain-query records across 15 pages for November 3–10 retrieved, plus saved named IDs within 76/76 combined records; incidental oncology/surgery matches excluded and retrieval not treated as full appraisal. Selected Alenura/suzetrigine/HNK sources appraised. Cebranopadol NDA excluded from this non-opioid topic because it activates mu-opioid receptors.

**Informal coverage:** Targeted Reddit/Journavx/podcast searches retrieved uncontrolled patient/clinician anecdotes with conflicting experiences, including Octoberdiscussion threads and November 4 comment. No general efficacy/approval inference. Original long-form recordings remain partial.

**Remaining gaps:** focused_incomplete; complete worldwide papers/supplements, non-US registries, regulator-label/hold census, original conference recordings and long-form informal-source appraisal remain incomplete. Full-success timestamps and baseline flags must remain unchanged.; Alenura effect sizes/CI/arm-level harms missing. Broad registry retrieval not exhaustive appraisal. Original full Xenon poster denominators and SUTKA protocol remain gaps; no fresh chronic-neuropathy efficacy established..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://vaneltix.com/alenura-delivers-positive-phase-2-results-in-interstitial-cystitis-bladder-pain-syndrome-trial/); [Source 2](https://clinicaltrials.gov/study/NCT05737121); [Source 3](https://clinicaltrials.gov/study/NCT07928011); [Source 4](https://clinicaltrials.gov/study/NCT07504601); [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28nonopioid+OR+pain+OR+%22NaV1.8%22+OR+suzetrigine%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-11-03%2C2026-11-10%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true).

### Kidney preservation and earlier detection

[Topic](../topics/17_kidney.md)

**Formal coverage:** Registry discovery September 5–November 10: 786/786 records over 8 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/study/NCT05936151); [Source 3](https://trials.lilly.com/en-US/trial/410437); [Source 4](https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2026-financial-results).

### Hearing and vision preservation/restoration

[Topic](../topics/18_hearing_vision.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 386/386 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 20 saved named records. Europe PMC returned 54/54 publication records for 2026-11-03 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Appraised ReBUILD and rechecked AC102/BIRD-1; sampled acquired-hearing and retinal primary abstracts. Kept inherited bestrophinopathy separate from dry AMD.

**Informal coverage:** Original AC102 purported-email thread re-opened; searched current tinnitus, BEST1 and AMD informal leads. No independent authenticated 2027 confirmation. Original sponsor email not available.

**Remaining gaps:** AC102 numerical results and 2027 trials remain unverified; inherited/common acquired treatment census and real-world combined retinal injection safety appraisal incomplete.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; The larger literature download was incomplete; the November 3–10 Europe PMC fallback was retrieved and screened, while earlier new-to-notebook items remain incompletely appraised..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22hearing+loss%22+OR+%22hearing+restoration%22+OR+tinnitus+OR+%22retinal+degeneration%22+OR+%22retinitis+pigmentosa%22+OR+%22macular+degeneration%22+OR+%22vision+restoration%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT03326336%2CNCT04676854%2CNCT04919473%2CNCT04945772%2CNCT05417126%2CNCT05776459%2CNCT05788536%2CNCT05919693%2CNCT06556368%2CNCT06571045%2CNCT06683742%2CNCT07024732%2CNCT07032038%2CNCT07185256%2CNCT07812090%2CNCT07826507%2CNCT07867080%2CNCT07878559%2CNCT07901751%2CNCT07920081&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22hearing+loss%22+OR+%22hearing+restoration%22+OR+tinnitus+OR+%22retinal+degeneration%22+OR+%22retinitis+pigmentosa%22+OR+%22macular+degeneration%22+OR+%22vision+restoration%22%29+AND+FIRST_PDATE%3A%5B2026-11-03+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://www.audiocure.com/ac102/); [Source 5](https://clinicaltrials.gov/study/NCT05776459); [Source 6](https://clinicaltrials.gov/study/NCT07185256); [Source 7](https://pubmed.ncbi.nlm.nih.gov/42982521/); [Source 8](https://pubmed.ncbi.nlm.nih.gov/42988264/); [Source 9](https://clinicaltrials.gov/study/NCT07927010); [Source 10](https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/).

### Hair loss, restoration and graying

[Topic](../topics/19_hair_loss.md)

**Formal coverage:** Thirty named records, 47 recent registry records and 290 paper-search records retrieved; the broader registry query timed out. VDPHL01 outcome-specific observed-data denominators, missing-data sensitivity and full common-harm tables remain gaps. Its extension cannot compare efficacy with ordinary minoxidil. PP405 female start remains estimated; ABS201 late-2026 readout not verified. CS001/CS002 dates remain inconsistent and cannot be identified as BQ002. Formal gray-hair programs and candidate-specific BQ002 trial/timing confirmation remain limited.

**Informal coverage:** Reopened the original PP405 September-recruitment, clascoterone launch and BQ002 posts and relevant company pages. Saved statuses are retained: PP405 partly corroborated; launch and BQ002 Phase 1 timing unconfirmed. November hair podcasts were inspected at description level, not as complete audio. No selected new specific rumor.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Thirty named records, 47 recent registry records and 290 paper-search records retrieved; the broader registry query timed out. VDPHL01 outcome-specific observed-data denominators, missing-data sensitivity and full common-harm tables remain gaps. Its extension cannot compare efficacy with ordinary minoxidil. PP405 female start remains estimated; ABS201 late-2026 readout not verified. CS001/CS002 dates remain inconsistent and cannot be identified as BQ002. Formal gray-hair programs and candidate-specific BQ002 trial/timing confirmation remain limited.; Reopened the original PP405 September-recruitment, clascoterone launch and BQ002 posts and relevant company pages. Saved statuses are retained: PP405 partly corroborated; launch and BQ002 Phase 1 timing unconfirmed. November hair podcasts were inspected at description level, not as complete audio. No selected new specific rumor..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://ir.veradermics.com/static-files/d4dd8d11-4237-43db-8bcc-afb6e26df9dd); [Source 2](https://clinicaltrials.gov/study/NCT06724614); [Source 3](https://clinicaltrials.gov/study/NCT07529977); [Source 4](https://clinicaltrials.gov/study/NCT07303322); [Source 5](https://www.reddit.com/r/tressless/comments/1wh8oo6/pelage_pharmaceuticals_phase_3_trials_for_pp405/); [Source 6](https://pelagepharma.com/press-releases/pp405-awaken-trial-first-patient-dosed/); [Source 7](https://www.reddit.com/r/tressless/comments/1v6rr61/clascoterone_wont_be_available_until_q4_2027_at/); [Source 8](https://www.cosmohealthconfidence.com/news/64300770-h1-2026); [Source 9](https://www.reddit.com/r/greyhairreversal/comments/1t0k55l/bioq_is_developing_an_injectable_drug_bq002/); [Source 10](https://www.bioq.com/).

### Skin aging, laxity and regeneration

[Topic](../topics/20_skin_aging.md)

**Formal coverage:** Twenty named records and 26 November 3–10 discovery records retrieved; the broader September 5 onward registry query timed out. The 87-record paper search was selectively appraised. New small Rejuran estimated starts remain unconfirmed. KB304 Phase 2 forecasts and trenibotE U.S. resubmission are not achievements. ASDS exosome/digital-toxin claims lacked complete numerical posters; no additional efficacy event selected.

**Informal coverage:** Revisited the October 30 management transcript: combination-study existence/start is now registry-corroborated, while end-2026 resubmission/mid-2027 U.S. decision remains a forecast. Indexed Reddit and skin-aging podcast/talk searches found no selected new specific rumor; full audio and ASDS Q&A were not appraised.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Twenty named records and 26 November 3–10 discovery records retrieved; the broader September 5 onward registry query timed out. The 87-record paper search was selectively appraised. New small Rejuran estimated starts remain unconfirmed. KB304 Phase 2 forecasts and trenibotE U.S. resubmission are not achievements. ASDS exosome/digital-toxin claims lacked complete numerical posters; no additional efficacy event selected.; Revisited the October 30 management transcript: combination-study existence/start is now registry-corroborated, while end-2026 resubmission/mid-2027 U.S. decision remains a forecast. Indexed Reddit and skin-aging podcast/talk searches found no selected new specific rumor; full audio and ASDS Q&A were not appraised..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://link.springer.com/article/10.1007/s00266-026-06404-y); [Source 2](https://clinicaltrials.gov/study/NCT07871513); [Source 3](https://stockanalysis.com/stocks/abbv/transcripts/721412-q3-2026/); [Source 4](https://clinicaltrials.gov/study/NCT07923448).

### Scar prevention, treatment and stretch marks

[Topic](../topics/21_scars.md)

**Formal coverage:** Twenty-two named records and 50 recent discovery records retrieved; the broader registry query timed out. The paper search failed twice and remains a material coverage gap. SCARFREE still lacks verified actual dosing; Geneva status and independent EU records remain unresolved. Earlier contradictory hydrocolloid outcome rows remain uninterpretable. The SNT-9465 sponsor pause is new; the original ANZCTR record is older and should not override later expansion reporting.

**Informal coverage:** Revisited indexed verteporfin status discussions and sponsor material. Animal, off-label and self-experiment descriptions do not establish trial efficacy. No selected new rumor; independent EU source-chain reconciliation, full investigator talks and comments remain gaps.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Twenty-two named records and 50 recent discovery records retrieved; the broader registry query timed out. The paper search failed twice and remains a material coverage gap. SCARFREE still lacks verified actual dosing; Geneva status and independent EU records remain unresolved. Earlier contradictory hydrocolloid outcome rows remain uninterpretable. The SNT-9465 sponsor pause is new; the original ANZCTR record is older and should not override later expansion reporting.; Revisited indexed verteporfin status discussions and sponsor material. Animal, off-label and self-experiment descriptions do not establish trial efficacy. No selected new rumor; independent EU source-chain reconciliation, full investigator talks and comments remain gaps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://newswire.iguana2.com/2fee0049d633f441/announcements/snt.asx/2A1709713/SNT_Syntara_Pauses_SNT-9465_Phase_1b_Recruitment.pdf); [Source 2](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=390538); [Source 3](https://syntaratx.com.au/news/); [Source 4](https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/).

### Facial volume restoration and contour

[Topic](../topics/22_facial_volume.md)

**Formal coverage:** Fifteen named records, 38 recent registry records and 24 paper-search records retrieved; the broader registry query timed out. Full HALO/HARMONY posters, matching registrations, detailed harms and later follow-up remain gaps. The under-eye rhPDGF-BB estimated November start has not been verified as actual. Broad international procedure/material safety coverage remains incomplete.

**Informal coverage:** Searched indexed Reddit/Adipeau discussions and GLP-1 facial-change podcast/talk leads. Available descriptions and sponsored interviews did not supply a selected new specific rumor or controlled outcome; full recordings and the older promotional source chains remain incompletely appraised.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Fifteen named records, 38 recent registry records and 24 paper-search records retrieved; the broader registry query timed out. Full HALO/HARMONY posters, matching registrations, detailed harms and later follow-up remain gaps. The under-eye rhPDGF-BB estimated November start has not been verified as actual. Broad international procedure/material safety coverage remains incomplete.; Searched indexed Reddit/Adipeau discussions and GLP-1 facial-change podcast/talk leads. Available descriptions and sponsored interviews did not supply a selected new specific rumor or controlled outcome; full recordings and the older promotional source chains remain incompletely appraised..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://news.abbvie.com/2026-11-08-Allergan-Aesthetics-Reports-Improved-Satisfaction-With-Facial-Appearance-Following-Aesthetic-Treatment-in-Two-Studies-of-Patients-on-GLP-1-Medications); [Source 2](https://link.springer.com/article/10.1007/s00266-026-06372-3); [Source 3](https://podcasts.apple.com/za/podcast/193-understanding-facial-changes-after-glp-1-weight/id1581084278?i=1000790916824).

### Pigmentation and uneven skin tone

[Topic](../topics/23_pigmentation.md)

**Formal coverage:** Eighteen named records, 23 recent registry records and 218 paper-search records retrieved; the broader registry query timed out. EB06 now records an actual August 5 start, while existing recruitment/late-2027 reporting expectations do not constitute new outcomes. TEV-53408 estimated November 16 start remains prospective. Non-vitiligo pigment conditions, independent registries and conference appendices remain incompletely appraised.

**Informal coverage:** Searched indexed Reddit and vitiligo/melasma podcast/talk leads, including the VR Foundation index. No selected new specific rumor. Existing anonymous participant descriptions do not substitute for posted outcomes; complete recordings/comments remain unappraised.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Eighteen named records, 23 recent registry records and 218 paper-search records retrieved; the broader registry query timed out. EB06 now records an actual August 5 start, while existing recruitment/late-2027 reporting expectations do not constitute new outcomes. TEV-53408 estimated November 16 start remains prospective. Non-vitiligo pigment conditions, independent registries and conference appendices remain incompletely appraised.; Searched indexed Reddit and vitiligo/melasma podcast/talk leads, including the VR Foundation index. No selected new specific rumor. Existing anonymous participant descriptions do not substitute for posted outcomes; complete recordings/comments remain unappraised..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/study/NCT07930039); [Source 2](https://www.vrfoundation.org/podcasts).

### Acne and rosacea

[Topic](../topics/24_acne_rosacea.md)

**Formal coverage:** Twenty named records, 87 September 5–November 10 registry discovery records and 205 paper-search records retrieved, with selective appraisal. AURORA NCT07863193 updated November 9 now records actual October 21 start; this verifies the already-recorded October first-dose announcement, not a second launch or result. It remains recruiting with 800 planned, August 2027 primary completion and April 2028 final completion estimates. The prior H2 2027 sponsor topline forecast remains distinct. SP0268, B244 and remibrutinib supplied no newly selected outcome. Allocation-ratio details in a November conference transcript were not corroborated in a primary document; full international/regulatory and rosacea-phenotype coverage remains incomplete.

**Informal coverage:** Searched indexed Reddit and acne/rosacea talk/podcast leads. A November 9 Sagimet conference-transcript lead was not fully reconciled with primary slides/audio. Previously saved Ontario/Florida recruitment anecdotes were not fully reopened this run. No selected new specific rumor; these are explicit gaps.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Twenty named records, 87 September 5–November 10 registry discovery records and 205 paper-search records retrieved, with selective appraisal. AURORA NCT07863193 updated November 9 now records actual October 21 start; this verifies the already-recorded October first-dose announcement, not a second launch or result. It remains recruiting with 800 planned, August 2027 primary completion and April 2028 final completion estimates. The prior H2 2027 sponsor topline forecast remains distinct. SP0268, B244 and remibrutinib supplied no newly selected outcome. Allocation-ratio details in a November conference transcript were not corroborated in a primary document; full international/regulatory and rosacea-phenotype coverage remains incomplete.; Searched indexed Reddit and acne/rosacea talk/podcast leads. A November 9 Sagimet conference-transcript lead was not fully reconciled with primary slides/audio. Previously saved Ontario/Florida recruitment anecdotes were not fully reopened this run. No selected new specific rumor; these are explicit gaps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/study/NCT07863193); [Source 2](https://www.investing.com/news/transcripts/sagimet-biosciences-at-guggenheim-healthcare-conference-acne-pivot-gains-traction-93CH-5012944).

### Dental alignment, regeneration and repair

[Topic](../topics/25_dental.md)

**Formal coverage:** Twenty-six named records, 28 recent registry records and 382 paper-search records retrieved; the broader registry query timed out. Laser RCT full text, complete harms and registry match remain gaps. A newly posted nanosilver-fluoride orthodontic-band protocol has no results and is not evidence of caries prevention. TRG035 Phase 2 actual dosing remains unverified. Root resorption, caries, occlusion and long-term retention cannot be inferred from material or early-alignment measurements.

**Informal coverage:** Searched indexed tooth-regrowth and orthodontic Reddit/talk/podcast leads. Recent TRG035 posts repeated earlier aspirations without verified human functional tooth regrowth or new trial results. Aligner-material interview audio was not fully appraised; no selected new specific rumor.

**Remaining gaps:** Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved.; Twenty-six named records, 28 recent registry records and 382 paper-search records retrieved; the broader registry query timed out. Laser RCT full text, complete harms and registry match remain gaps. A newly posted nanosilver-fluoride orthodontic-band protocol has no results and is not evidence of caries prevention. TRG035 Phase 2 actual dosing remains unverified. Root resorption, caries, occlusion and long-term retention cannot be inferred from material or early-alignment measurements.; Searched indexed tooth-regrowth and orthodontic Reddit/talk/podcast leads. Recent TRG035 posts repeated earlier aspirations without verified human functional tooth regrowth or new trial results. Aligner-material interview audio was not fully appraised; no selected new specific rumor..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42988646/); [Source 2](https://doi.org/10.1016/j.ejwf.2026.08.003); [Source 3](https://clinicaltrials.gov/study/NCT07926035); [Source 4](https://innovationindentistry.com/podcasts/orthodontics-in-summary).

### Allergy and airway disease

[Topic](../topics/26_allergy_airway.md)

**Formal coverage:** Reviewed the full saved topic corpus, scope and state. Retrieved all 122 ClinicalTrials.gov November 3–10 discovery records across two pages and all named records within 71 combined airway/infection IDs. Appraised original WIN378 filing, named protocols and selected regulator/sponsor/paper results. Worldwide appraisal back to the September overlap remains incomplete. Deduplicated lebrikizumab’s November 10 CT.gov posting against July 1, 2017 EU results: the primary adjusted contrasts were already public, with no demonstrated additional steroid sparing. No new result event added.

**Informal coverage:** Targeted Viaskin, rademikibart, asthma/COPD Reddit and talk searches mainly returned known sponsor forecasts, patient accounts and an indexed October 21 Surya Bhatt interview discussing existing SEABREEZE data. No distinct new attributed claim was selected. Full recordings remain unappraised.

**Remaining gaps:** Complete worldwide literature, non-U.S. registries, regulator and safety census and original audio/Q&A are unfinished. Do not advance full successful-check dates.; WIN378 Phase 2/3 versus registry Phase 2 and sponsor additional versus registry overall enrollment remain unreconciled; no established severe-exacerbation benefit.; Proactive e-consult COPD results require separate appraisal. GSK combination NCT07915791 remained not yet recruiting after the November 9 estimate..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://www.sec.gov/Archives/edgar/data/2145089/000119312526452536/d111653df1a.htm); [Source 2](https://clinicaltrials.gov/study/NCT07120503); [Source 3](https://clinicaltrials.gov/study/NCT07646587); [Source 4](https://seekingalpha.com/article/4957116-connect-biopharma-holdings-limited-cntb-discusses-rademikibart-and-seabreeze-trial-results-in); [Source 5](https://clinicaltrials.gov/study/NCT01987492); [Source 6](https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000190-24/results).

### Infectious-disease prevention and treatment

[Topic](../topics/27_infectious_disease.md)

**Formal coverage:** Reviewed the full saved topic corpus, scope and state. Retrieved all 260 ClinicalTrials.gov November 3–10 discovery records across three pages and all named records within 71 combined airway/infection IDs. Appraised primary Shigella, chikungunya, antibiotic and hepatitis B/delta sources; three HBV/HDV raw registries verified comparison windows and trial identities. Worldwide appraisal back to the September overlap remains incomplete.

**Informal coverage:** Revisited the original RadicalNumerics blog and found an original Podovirus patient-advocate transcript. Later Omnii coverage traces to the same developer claim; no independently verified clinical course or authorization was recovered. Searches for the earlier adibelivir administrative and anonymous Mayo UTI phage leads did not verify a new formal event. Full audio and precise original comment links remain gaps.

**Remaining gaps:** Complete worldwide literature, non-U.S. registries, regulator and safety census and original audio/Q&A are unfinished. Do not advance full successful-check dates.; S4V2 exact challenge denominators, effect size and detailed harms remain unavailable. IXCHIQ five-year full attrition and clinical efficacy are not established.; EMA phage workshop proceedings, GSK HSV vaccine detailed results and new rifaximin/azithromycin diarrhea tables remain unappraised. Flu/COVID combination NCT07890454 remained not yet recruiting after the November 9 estimate.; HBV/HDV full conference talks, webcast recordings, complete harms and long-term clinical outcomes remain unappraised; unequal comparison windows and selected withdrawal denominators are preserved..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://www.globenewswire.com/news-release/2026/11/10/3399143/0/en/valneva-reports-sustained-94-seroresponse-five-years-after-a-single-dose-of-chikungunya-vaccine-ixchiq.html); [Source 2](https://valneva.com/press-release/valneva-reports-sustained-94-seroresponse-five-years-after-a-single-dose-of-chikungunya-vaccine-ixchiq/); [Source 3](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-permanent-discontinuations); [Source 4](https://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety); [Source 5](https://www.accessdata.fda.gov/scripts/purplebooksearch/index.cfm?event=advancedsearch); [Source 6](https://www.globenewswire.com/news-release/2026/11/09/3398042/0/en/valneva-announces-positive-phase-2-results-for-tetravalent-shigella-vaccine-candidate-s4v2.html); [Source 7](https://valneva.com/wp-content/uploads/2026/11/2026_11_09_S4V2_Infant-CHIM_Phase-2_Results_PR_EN.pdf); [Source 8](https://clinicaltrials.gov/study/NCT06615375); [Source 9](https://clinicaltrials.gov/study/NCT06523231); [Source 10](https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Announces-Primary-Endpoint-Met-in-Pivotal-Phase-3-ECLIPSE-1-Trial-for-Elebsiran-and-Tobevibart-in-Chronic-Hepatitis-Delta/default.aspx); [Source 11](https://clinicaltrials.gov/study/NCT06903338); [Source 12](https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Announces-Expanded-Phase-2-SOLSTICE-Data-for-Elebsiran-and-Tobevibart-in-Chronic-Hepatitis-Delta-Showing-Deep-and-Sustained-Viral-Suppression-and-Exploratory-Finite-Treatment-Data/default.aspx); [Source 13](https://clinicaltrials.gov/study/NCT05461170); [Source 14](https://precisionbiosciences.gcs-web.com/node/12336/pdf); [Source 15](https://www.businesswire.com/news/home/20261105643191/en/); [Source 16](https://clinicaltrials.gov/study/NCT06680232); [Source 17](https://journals.asm.org/doi/full/10.1128/aac.00390-26); [Source 18](https://clinicaltrials.gov/study/NCT05645757); [Source 19](https://pmc.ncbi.nlm.nih.gov/articles/PMC13643602/); [Source 20](https://pubmed.ncbi.nlm.nih.gov/42846794/); [Source 21](https://doi.org/10.1093/ofid/ofag608); [Source 22](https://clinicaltrials.gov/study/NCT03162250); [Source 23](https://www.radicalnumerics.ai/blog/omnii-phage); [Source 24](https://phage.directory/podovirus/phage-therapy-from-the-perspective-of-a-cf-patient-advocate); [Source 25](https://www.ema.europa.eu/en/events/european-medicines-agency-workshop-bacteriophage-therapy).

### Genetic screening and risk prediction

[Topic](../topics/28_genetic_screening.md)

**Formal coverage:** Registry discovery September 5–November 10: 106/106 records over 2 pages, complete retrieval; selected relevant new protocols/results/status changes appraised. All 230 saved named IDs across these nine topics retrieved. Targeted dated regulator, investigator, paper and sponsor checks.

**Informal coverage:** Targeted Reddit, podcast/talk, sponsor Q&A and original-source searches sampled; existing relevant claims revisited without treating reposts or popularity as corroboration. No distinct new source-grounded informal efficacy/approval claim selected.

**Remaining gaps:** Focused incomplete worldwide appraisal; all retrieved records and every original paper/supplement not appraised.; Non-U.S. registers, complete regulator/hold/discontinuation and source-audio/transcript coverage remain incomplete..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28polygenic+risk+screening+OR+embryo+selection+OR+newborn+genomic+screening+OR+pharmacogenomic+screening+OR+cascade+testing%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=100&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://ir.genedx.com/static-files/ea80ac10-71d9-40ed-832f-79617ca067e2); [Source 3](https://www.health.state.mn.us/people/newbornscreening/program/announcements.html).

### Insomnia

[Topic](../topics/29_sleep_insomnia.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 1464/1464 records across 2 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 13 saved named records. Europe PMC returned 28/28 publication records for 2026-11-03 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Verified pediatric daridorexant designation from original sponsor and DARI-DREAM recruitment. SOM001 still masks identities and describes weekly switching despite parallel label. Checked the recent ADHD/ASD DORA review as secondary context.

**Informal coverage:** Sampled daridorexant/DORA patient threads and sponsor presentation/interview leads, re-opened cross-topic ENLIGHTEN6 and TAK-360 reports. Individual treatment experiences do not establish trial allocation, architecture or incidence; no new program rumor selected.

**Remaining gaps:** No complete drug/digital/behavioral baseline, original pediatric CTIS full results, adult/pediatric long-term harms, REM/N3 comparison or unidentified SOM001 doses; perioperative lemborexant start estimates not resolved.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; The larger literature download was incomplete; the November 3–10 Europe PMC fallback was retrieved and screened, while earlier new-to-notebook items remain incompletely appraised.; Inherited baseline is incomplete; preserve baseline flags and successful-check timestamps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+CBT-I+OR+daridorexant+OR+lemborexant%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+CBT-I+OR+daridorexant+OR+lemborexant%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc&pageToken=ZVNj7o2Elu8o3lpyXdC5577umpOQJJxuYvil1PUYlD6SuP08FCfCFfbR99pM1iI); [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT04287062%2CNCT05423717%2CNCT06823752%2CNCT07542756%2CNCT07743931%2CNCT07843329%2CNCT07872007%2CNCT07876661%2CNCT07880561%2CNCT07903038%2CNCT07903051%2CNCT07911826%2CNCT07920185&pageSize=1000&format=json); [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28insomnia+OR+CBT-I+OR+daridorexant+OR+lemborexant%29+AND+FIRST_PDATE%3A%5B2026-11-03+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 5](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1969750/pdf); [Source 6](https://clinicaltrials.gov/study/NCT07920185); [Source 7](https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3798577); [Source 8](https://clinicaltrials.gov/study/NCT05423717); [Source 9](https://clinicaltrials.gov/study/NCT07843329); [Source 10](https://www.idorsia.com/media/news/news-archive/media-release-details?id=3791556); [Source 11](https://www.reddit.com/r/insomnia/comments/1xj0lz7/orexin_receptor_antagonists_stopped_working/); [Source 12](https://www.idorsia.com/investors/news-and-events/investor-webcasts); [Source 13](https://www.reddit.com/r/Narcolepsy/comments/1x6wae1/a_question_for_anyone_doing_an_orexin_agonist/); [Source 14](https://clinicaltrials.gov/study/NCT06952699); [Source 15](https://www.reddit.com/r/Eloralintide/comments/1x1if30/hows_your_trial_going_weekly_update_post_let_us/).

### Obstructive sleep apnea

[Topic](../topics/30_sleep_apnea.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 207/207 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 13 saved named records. Europe PMC returned 27/27 publication records for 2026-11-03 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Verified VESPER-OSA2 recruitment and sampled screening validation and stimulation registries; AD109 prior primary tables deduplicated.

**Informal coverage:** Reopened the Mehra October 22 interview and sampled AD109/OSA informal discussion. No new independent complete menopause table or distinct rumor selected. No new launch claim inferred.

**Remaining gaps:** Full CHEST menopause tables, CV outcome evidence, external validation and all device/therapy trials not appraised. Single-arm ring-derived AHI protocol is not PSG validation or outcomes evidence.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; The larger literature download was incomplete; the November 3–10 Europe PMC fallback was retrieved and screened, while earlier new-to-notebook items remain incompletely appraised.; Inherited baseline is incomplete; preserve baseline flags and successful-check timestamps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22obstructive+sleep+apnea%22+OR+AD109+OR+%22sleep+apnoea%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT04153240%2CNCT05811247%2CNCT05813275%2CNCT05929066%2CNCT05929079%2CNCT07225686%2CNCT07635563%2CNCT07767942%2CNCT07823608%2CNCT07846865%2CNCT07881757%2CNCT07898254%2CNCT07898618&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22obstructive+sleep+apnea%22+OR+AD109+OR+%22sleep+apnoea%22%29+AND+FIRST_PDATE%3A%5B2026-11-03+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://ir.apnimed.com/news-events/news-releases); [Source 5](https://clinicaltrials.gov/study/NCT07921329); [Source 6](https://pubmed.ncbi.nlm.nih.gov/42989067/); [Source 7](https://pubmed.ncbi.nlm.nih.gov/42993419/); [Source 8](https://clinicaltrials.gov/study/NCT07881757); [Source 9](https://www.hcplive.com/view/ad109-greater-osa-improvements-postmenopausal-women).

### Narcolepsy & excessive sleepiness

[Topic](../topics/31_sleep_hypersomnolence.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 22/22 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 9 saved named records. Europe PMC returned 55/55 publication records for 2026-09-05 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Read DEA interim final rule and filed stamp, current Takeda U.S. launch forecast and saved narcolepsy/IH registries. No U.S. pharmacy availability inferred.

**Informal coverage:** Re-opened both original launch predictions and original TAK-360 account. November 3–6 forecast is stale/unresolved; official public-inspection rule supplies a scheduling date, not commercial access. New Reddit post follows the same primary document.

**Remaining gaps:** November 12 official publication, actual U.S. distribution/coverage, long-term orexin efficacy/safety and complete IH/NT2 literature remain unverified.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; Inherited baseline is incomplete; preserve baseline flags and successful-check timestamps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28narcolepsy+OR+%22idiopathic+hypersomnia%22+OR+%22orexin+agonist%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT06752668%2CNCT06767683%2CNCT06812078%2CNCT06843590%2CNCT06952699%2CNCT07598708%2CNCT07625280%2CNCT07646678%2CNCT07871006&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28narcolepsy+OR+%22idiopathic+hypersomnia%22+OR+%22orexin+agonist%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://www.takeda.com/en-us/); [Source 5](https://clinicaltrials.gov/study/NCT06952699); [Source 6](https://public-inspection.federalregister.gov/2026-23075.pdf); [Source 7](https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-second-quarter-fy2026-results/); [Source 8](https://www.reddit.com/r/Narcolepsy/comments/1xs44fp/orzeyful_publishing_scheduled_for_thursday/); [Source 9](https://www.reddit.com/r/Narcolepsy/comments/1xsec07/orzeyful_rule_published_nov_9_2026_415_pm_eastern/); [Source 10](https://www.reddit.com/r/Narcolepsy/comments/1x6wae1/a_question_for_anyone_doing_an_orexin_agonist/); [Source 11](https://www.reddit.com/r/Narcolepsy/comments/1xm076k/oveporexton_orzeyful_we_are_almost_there/); [Source 12](https://www.reddit.com/r/Narcolepsy/comments/1xnm6fn/orzeyful_sleep_physician/).

### Circadian rhythm disorders

[Topic](../topics/32_sleep_circadian.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 94/94 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 5 saved named records. Europe PMC returned 157/157 publication records for 2026-09-05 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Checked tasimelteon delayed-phase, Non-24, shift-work protocols and sponsor jet-lag hearing status, separating current indication from hearing. November 9 jet-lag hydrocortisone/melatonin registry update is an old completed trial, not new efficacy. No selected material delta from these sources.

**Informal coverage:** Targeted Reddit and talk searches for tasimelteon, delayed phase, Non-24 and shift work were sparse; did not obtain a new attributable development lead or complete hearing/audio record.

**Remaining gaps:** Court outcome and December 14–18 jet-lag hearing not yet verified as occurred; full earlier baseline, sustained entrainment/function and worldwide circadian trial appraisal incomplete.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; Inherited baseline is incomplete; preserve baseline flags and successful-check timestamps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22circadian+rhythm%22+OR+%22delayed+sleep+phase%22+OR+%22non-24%22+OR+tasimelteon%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT03715465%2CNCT04652882%2CNCT06568367%2CNCT07869901%2CNCT07883291&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22circadian+rhythm%22+OR+%22delayed+sleep+phase%22+OR+%22non-24%22+OR+tasimelteon%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://clinicaltrials.gov/study/NCT00097474); [Source 5](https://clinicaltrials.gov/study/NCT04652882); [Source 6](https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm).

### Restless legs syndrome

[Topic](../topics/33_sleep_restless_legs.md)

**Formal coverage:** Loaded the full saved topic corpus for trial/source/anchor extraction and appraised recent notes and relevant earlier program context against 769 saved event keys. Retrieved 18/18 records across 1 pages of the specified ClinicalTrials.gov September 5–November 10 discovery query and 8 saved named records. Europe PMC returned 31/31 publication records for 2026-09-05 through November 10. Retrieval/metadata screening is not complete individual clinical appraisal. Rechecked saved CT10, extended-duration TOMAC and refractory iron/device records; no material result selected from this bounded review. CT10 remains a stale not-yet-recruiting record despite elapsed April 2026 estimated start.

**Informal coverage:** Sampled original patient discussions about Nidra/TOMAC; anecdotal benefit or difficulties do not establish a new clinical result or generally available coverage. No distinct program rumor selected.

**Remaining gaps:** No verified actual CT10 start, comprehensive long-term augmentation/function evidence or full device, iron and medicine safety appraisal; inherited baseline remains incomplete.; This is a focused appraisal, not a complete worldwide review of trial registries, papers/supplements, approval/availability, holds and rare harms, or original long-form informal material.; Inherited baseline is incomplete; preserve baseline flags and successful-check timestamps..

**Full check completed:** No. Original successful-check date/baseline flag retained.

**Selected checked sources:** [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22restless+legs%22+OR+TOMAC+OR+Nidra%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-11-10%5D&pageSize=1000&format=json&countTotal=true&sort=LastUpdatePostDate%3Adesc); [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT04874155%2CNCT05196828%2CNCT07179406%2CNCT07224932%2CNCT07397247%2CNCT07675109%2CNCT07780032%2CNCT07822607&pageSize=1000&format=json); [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22restless+legs%22+OR+TOMAC+OR+Nidra%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-11-10%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000&sort_date=y); [Source 4](https://clinicaltrials.gov/study/NCT07397247); [Source 5](https://clinicaltrials.gov/study/NCT07675109); [Source 6](https://clinicaltrials.gov/study/NCT07822607); [Source 7](https://www.reddit.com/r/RestlessLegs/comments/1xgugru/has_anyone_been_to_the_point_of_actually_going/).

## Rumor and informal-signal revisits

- **obicetrapib_attia_davidson_2026_09_14_alz_prevention_discussion — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **Wegovy_2026-09-18_CHMP-MASH-outcome-unclear — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **nucleus_vitruvian_2026-09-27_IQ_claim — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **PEARL24month_Vitaei_2026-04-11_claim — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **regal_reddit_2026_10_02_event80_anyday_inference — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **SOLIS1_tolerability_Reddit_2026-10-08 — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **enlighten6-informal-week9 — unchanged.** Targeted source-chain revisit; prior uncertainty/history preserved, no repeat alert. Full original audio/claim verification remains incomplete.
- **lm11a31_longo_brainstorm_phase2b3_planning — unconfirmed.** Reopened original Longo episode/transcript. Study design and funding need remain planning, not registration/start or a dementia-prevention result. No new AD confirmatory registry hit selected.
- **usona_nda_anonymous_report_2026-11-02 — unconfirmed.** Original public introduction re-opened; full article still paywalled. Usona public pipeline and current FDA/sponsor searches did not establish completion/acceptance. Compass submission is a separate product and indication.
- **comp360_reddit_2026_10_12_review_timing_inference — unconfirmed.** Pale-Shoe3160 original 44–81-day inference re-read. November 9 sponsor filing confirms the starting milestone, not the community-calculated review duration or an FDA action date. Earlier end-October filing scenario elapsed.
- **resilient_mdma_doblin_q12027_prediction_2026_10_23 — unconfirmed.** Original Reddit reproduction re-read; complete original interview/event audio not obtained. No independent FDA acceptance, waiver or decision timing established. New social-anxiety trial is separate.
- **ac102_reddit_email_2026_08_29_phase3_tinnitus_2027 — corroborated but unconfirmed.** Original purported-email thread and registry rechecked. Actual Phase 2 completion corroborates one part; 2027 Phase 3/tinnitus plans and outcomes remain unverified.
- **ad109-menopause-2026-10-22-investigator-interview — unconfirmed.** Original Mehra interview re-opened; subgroup remains exploratory. No original complete CHEST subgroup denominators or formal comparative result selected.
- **tak360-kyra-fragmentation-informal — unconfirmed.** Original self-reported extension account re-read. No verified dose, assignment, polysomnography or aggregate causality; no status change.
- **orzeyful-2026-11-02-informal-specific-launch-window — stale/unresolved.** November 3–6 predicted availability elapsed. The November 9 DEA public-inspection filing corroborates the Schedule IV step but specifies November 12 publication/effectiveness; this does not prove a pharmacy launch. The November 4 later-window hunch remains unconfirmed. New threads repeat the rule and speculate about access without independent commercial confirmation.
- **enobosarm_2026-09-09_cantor_phase3-direction — unconfirmed.** November9Verurelease describes scheduled post-hocQUALITYreport and existingPLATEAU Phase 2b; proposed4,500-person Phase 3scale/start not confirmed. Original Cantor audio still not appraised.
- **tgc_december_timing_secondary_report — unconfirmed.** E-DailySeptember18Decemberforecast recovered/revisited; originalshareholderrecording/primarytimingconfirmation missing. CurrentNCT03203330record hasnoresults; noefficacyprediction confirmed.
- **mount_sinai_2026-09-22_ibd_cart_planning — unconfirmed.** OriginalOncLiveplanning summary and MountSinaiIBD/sourceleads revisited; no matching newformaltrial initiation/firstdoseverified. SeparateCARcohorts andenterocolitisresearch do notconfirm thisprogram.
- **omnii-phage-compassionate-administration — unconfirmed.** Revisited the original RadicalNumerics blog and found an original Podovirus patient-advocate transcript. Later Omnii coverage traces to the same developer claim; no independently verified clinical course or authorization was recovered. Searches for the earlier adibelivir administrative and anonymous Mayo UTI phage leads did not verify a new formal event. Full audio and precise original comment links remain gaps.
- **infectious_disease — unconfirmed.** Revisited the original RadicalNumerics blog and found an original Podovirus patient-advocate transcript. Later Omnii coverage traces to the same developer claim; no independently verified clinical course or authorization was recovered. Searches for the earlier adibelivir administrative and anonymous Mayo UTI phage leads did not verify a new formal event. Full audio and precise original comment links remain gaps.
- **allergy_airway — no_new_claim_selected.** Targeted Viaskin, rademikibart, asthma/COPD Reddit and talk searches mainly returned known sponsor forecasts, patient accounts and an indexed October 21 Surya Bhatt interview discussing existing SEABREEZE data. No distinct new attributed claim was selected. Full recordings remain unappraised.
- **pp405_september2026_recruitment_rumor — corroborated but unconfirmed in part.** Original Reddit post and sponsor first-dose announcement revisited. Registry records actual September 21 start and sponsor announced first dosing October 14; the alleged earlier email and exact first-dose timing remain unverified.
- **clascoterone_2026-07-26_reddit_us-launch-inference — unconfirmed.** Original Reddit launch inference and Cosmo July company update revisited. Filing forecasts do not verify a late-2027/2028 U.S. launch, actual submission or approval.
- **bq002_2026-05-01_reddit_phase1-2027 — unconfirmed.** Original Reddit post and BioQ candidate page revisited. Candidate existence does not substantiate the 2027 Phase 1 assertion. No candidate-specific formal human registry/date was verified in this review; CS001/CS002 are not silently identified as BQ002.
- **trenibote_call_resubmission_mid2027_2026-10-30 — unconfirmed.** Third-party transcript management forecast re-opened. Combination-study existence/start now corroborated by NCT07871513; this does not confirm actual U.S. resubmission or a mid-2027 regulatory decision. Original full audio/FDA correspondence not appraised.

## Notebook and publication

Stable topic IDs, paths, browse groups, all personal-note sections, original dated history and prior note anchors are preserved. The retained sleep hub is unchanged and is not an extra monitoring assignment. Partial retrieval/appraisal gaps are not labeled no news. State is advanced only after saved notes and links are verified.

The November 7 HORIZON homepage study was reviewed and retained; its previously unknown ASCVD program status is corrected from the original October letter and November registry. Numerical trial plots and historical curves are preserved; affected development histories, program status, safety context and milestones are reconciled. Website publication is recorded separately after validation and confirmed deployment.